Related Experiment Videos
Antigen presentation to naive CD4 T cells in the lymph node.
Andrea A Itano1, Marc K Jenkins
1Department of Microbiology and the Center for Immunology, University of Minnesota, MMC 334, 420 Delaware St. SE, Minneapolis, Minnesota 55455, USA.
Nature Immunology
|July 31, 2003
Summary
Antigen presentation of peptide-major histocompatibility complex class II (pMHC class II) complexes to CD4 T cells in vivo is complex. This review explores lymph node architecture, antigen-presenting cells (APCs), and T cell activation to understand this process within its microenvironment.
Area of Science:
- Immunology
- Cell Biology
Background:
- In vitro studies extensively detail peptide-major histocompatibility complex class II (pMHC class II) complex presentation to CD4 T cells.
- In vivo antigen presentation occurs within a complex microenvironment, unlike controlled in vitro settings.
Purpose of the Study:
- To review current understanding of in vivo antigen presentation within lymph nodes.
- To elucidate how lymph node architecture, antigen-presenting cell (APC) subsets, and T cell activation influence pMHC class II presentation.
Main Methods:
- Review of recent developments in immunology and cell biology research.
- Analysis of studies focusing on lymph node architecture and cellular interactions.
- Synthesis of findings on APC subsets and T cell activation dynamics.
Main Results:
- In vivo antigen presentation is constrained by the complex lymph node microenvironment.
- Specific APC subsets and their migratory patterns are crucial for effective T cell priming.
- T cell activation is tightly regulated by the spatial and temporal context of pMHC class II presentation.
Conclusions:
- Understanding in vivo antigen presentation requires considering the intricate interplay of anatomical and cellular factors.
- Advances in visualizing lymph node dynamics are crucial for deciphering T cell-mediated immune responses.
- Further research into the in vivo behavior of APCs and T cells will refine our knowledge of adaptive immunity.